Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020180733 - EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF

Publication Number WO/2020/180733
Publication Date 10.09.2020
International Application No. PCT/US2020/020505
International Filing Date 28.02.2020
IPC
C12N 5/0783 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
CPC
C12N 2501/2302
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2501Active agents used in cell culture processes, e.g. differentation
20Cytokines; Chemokines
23Interleukins [IL]
2302Interleukin-2 (IL-2)
C12N 2501/51
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2501Active agents used in cell culture processes, e.g. differentation
50Cell markers; Cell surface determinants
51B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
C12N 2501/515
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2501Active agents used in cell culture processes, e.g. differentation
50Cell markers; Cell surface determinants
515CD3, T-cell receptor complex
C12N 2501/603
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2501Active agents used in cell culture processes, e.g. differentation
60Transcription factors
603Oct-3/4
C12N 5/0638
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor;
06Animal cells or tissues; Human cells or tissues
0602Vertebrate cells
0634Cells from the blood or the immune system
0636T lymphocytes
0638Cytotoxic T lymphocytes [CTL], lymphokine activated killer cells [LAK]
Applicants
  • IOVANCE BIOTHERAPEUTICS, INC. [US]/[US]
Inventors
  • KARYAMPUDI, Lavakumar
Agents
  • GRIFFIN, Gail, H.
  • CHAI, Deping
  • BEARDELL, Louis, W.
  • CAO, Ping
  • DAVIS, Kenneth, J.
Priority Data
62/812,90001.03.2019US
62/857,21904.06.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF
(FR) EXPANSION DE LYMPHOCYTES INFILTRANT LES TUMEURS À PARTIR DE TUMEURS LIQUIDES ET LEURS UTILISATIONS THÉRAPEUTIQUES
Abstract
(EN)
Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetically modified T cell receptors, and other genetic modifications, and uses of such expanded and/or modified PBLs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.
(FR)
L'invention concerne des procédés d'expansion de lymphocytes circulants à partir du sang de patients atteints de malignités hématologiques, y compris les lymphomes et les leucémies, des modifications génétiques de lymphocytes circulants étendus pour incorporer des récepteurs d'antigènes chimériques, des récepteurs de lymphocytes T génétiquement modifiés, et d'autres modifications génétiques, et des utilisations de ces lymphocytes circulants étendus et/ou modifiés dans le traitement de maladies telles que des cancers et des malignités hématologiques.
Latest bibliographic data on file with the International Bureau